Cargando…
A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials
We describe a Bayesian adaptive design for early phase cancer trials of a combination of three agents. This is an extension of an earlier work by the authors by allowing all three agents to vary during the trial and by assigning different drug combinations to cohorts of three patients. The primary o...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505662/ https://www.ncbi.nlm.nih.gov/pubmed/28706582 http://dx.doi.org/10.3844/amjbsp.2016.1.11 |